Max Osipov

Max Osipov is currently the Director of Medicinal Chemistry at Septerna, a role they have held since 2025. Prior to this, Max served as Associate Director of Small Molecule Discovery at Tenvie Therapeutics and held multiple positions at Denali Therapeutics, including Associate Director and Principal Scientist. Max's earlier experiences include significant roles in medicinal chemistry at Flexus Biosciences and FLX Bio, Inc., and they earned a PhD in Organic Chemistry from Stanford University, where they were advised by Barry M. Trost. Max also holds a Bachelor of Science degree in Chemistry from the University of Pittsburgh.